Melanoma suppressing functions of carcinoma oncogene FOXQ1
Melanoma suppressing functions of carcinoma oncogene FOXQ1
批准号:
9024029
负责人:
Mikhail Nikiforov
金额:
$18.65万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-12-01 至 2017-11-30
关键词:
AffectAgreementCDH1 geneCarcinomaCell Adhesion MoleculesCell LineCell-Cell AdhesionCellsDataData AnalysesDevelopmentE-CadherinEpithelialEpithelial CellsFOXQ1 geneFamilyGenesGenetic TranscriptionHealthHumanKnock-outLightMalignant Epithelial CellMalignant NeoplasmsMelanoma CellMesenchymalMetalloproteasesMetastatic CarcinomaMetastatic MelanomaModelingMolecularMonomeric GTP-Binding ProteinsMusN-CadherinNeoplasm MetastasisOncogenesPathway interactionsPatientsPhenotypePrimary CarcinomaProcessProcessed GenesProteinsPublishingRegulationRepressionResistanceRoleSpecimenStagingSuppressor GenesTWIST1 geneTestingThe Cancer Genome AtlasTherapeutic InterventionTissuesTransactivationTumor Suppressor ProteinsTumorigenicityUp-Regulationbasechemotherapydesignfunctional restorationin vivomalignant phenotypemelanocytemelanomamembermicrophthalmia-associated transcription factormouse modelnoveloverexpressionrestorationrhotranscription factortumortumor progression
中文摘要
描述(申请人提供):恶性黑色素瘤是人类最具侵袭性的癌症之一。它的转移能力,加上对传统抗癌化疗的耐药性,使得黑色素瘤极难治愈。因此,转移性黑色素瘤患者的中位生存期仅为8.5个月。黑色素瘤细胞侵袭是转移的先决条件,通常包括细胞-细胞黏附分子E-钙粘附素(CDH1)的丢失。在上皮细胞中,E-钙粘附素的丢失是上皮-间充质转化(EMT)的一个标志,通过这个过程,静态上皮细胞获得间质样表型,包括迁移能力。在癌症中,EMT促进侵袭性表型,而侵袭性表型是转移扩散所必需的。为了寻找调节黑色素瘤细胞中EMT样转化的转录因子,我们评估了几种真正的癌症EMT调节因子。其中FOXQ1是Fox转录因子家族的成员之一,在多种人类肿瘤的晚期过表达。FOXQ1通过上调EMT转录因子(EMT-TF)ZEB2和Twist1促进EMT,最终抑制CDH1。出乎意料的是,我们发现与正常的人黑素细胞(NHM)相比,转移性黑色素瘤细胞中FOXQ1的表达受到强烈抑制。因此,TCGA数据分析显示,与原发黑色素瘤相比,转移性黑色素瘤样本中FOXQ1的水平显著降低。此外,基于TCGA的分析和已发表的研究发现,转移性黑色素瘤中其他几种EMT-TF的水平高于原发癌,而转移性黑色素瘤的水平低于原发黑色素瘤。我们发现,FOXQ1水平的恢复抑制了所有测试黑色素瘤细胞的恶性表型,而不依赖于它们的小眼球相关转录因子(MITF)的状态,MITF是黑素细胞谱系发育所必需的转录因子。此外,FOXQ1通过MITF依赖和
--独立的道路。因此,我们将在人类黑色素瘤细胞中确定FOXQ1肿瘤抑制活性的机制,并在小鼠黑色素瘤模型中确定Foxq1缺陷在促进黑色素瘤形成中的作用。除了对黑色素瘤细胞中一种新的肿瘤抑制因子进行机制分析外,我们的研究还将揭示一个有趣的机制,即转录调节因子如何在肿瘤进展的同一阶段发挥肿瘤抑制因子或癌基因的作用,这取决于癌症的组织来源。
英文摘要
DESCRIPTION (provided by applicant): Malignant melanoma is one of the most aggressive types of human cancers. Its ability to metastasize in combination with resistance to conventional anticancer chemotherapy makes melanoma extremely difficult to cure. As a consequence, the median survival of patients with metastatic melanoma is merely 8.5 months. Melanoma cell invasion, a prerequisite for metastases, often includes loss of a cell-cell adhesion molecule E-cadherin (CDH1). In epithelial cells, loss of E-cadherin is a hallmark of epithelial-mesenchymal transition (EMT), a process by which static epithelial cells acquire a mesenchymal-like phenotype, including migratory capability. In carcinomas, EMT promotes invasive phenotypes which are essential for metastatic dissemination. In search for transcription factors regulating the EMT-like transition in melanoma cells, we evaluated several bona fide regulators of carcinoma EMT. One of them, FOXQ1, a member of FOX family of transcription factors, is overexpressed at advanced stages in multiple human carcinomas. FOXQ1 promotes EMT through upregulation of EMT transcription factors (EMT-TF) ZEB2 and TWIST1, ultimately resulting in repression of CDH1. Unexpectedly, we found that FOXQ1 expression is strongly inhibited in metastatic melanoma cells compared to normal human melanocytes (NHM). Accordingly, TCGA data analysis revealed that FOXQ1 levels are significantly lower in metastatic melanoma specimens compared to primary melanomas. Moreover, TCGA-based analysis and published studies identified that levels of several other EMT-TFs that are higher in metastatic vs primary carcinomas are instead lower in metastatic vs primary melanomas.. We found that restoration of FOXQ1 levels suppresses malignant phenotypes in all tested melanoma cells independent of their status of microphthalmia-associated transcription factor (MITF), a transcription factor essential for the development of the melanocyte lineage. Moreover, FOXQ1 inhibits multiple transformed phenotypes via MITF-dependent and
-independent pathways. Therefore, we will identify mechanisms of FOXQ1 tumor suppressor activities in human melanoma cells and determine the role of Foxq1 deficiency in promotion of melanomagenesis in a mouse model of melanoma. In addition to the mechanistic analysis of a novel tumor suppressor in melanoma cells, our studies will shed light on an intriguing mechanism of how a transcriptional regulator can act as a tumor suppressor or as an oncogene at the same stage of tumor progression depending on the tissue origin of cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of regulation and subcellular localization of GTP biosynthesis in melanoma invasion and metastasis
-
批准号:10636058
-
项目类别:
-
资助金额:$55.52万
-
财政年份:2023
-
负责人:Mikhail Nikiforov
-
依托单位:
Bidirectional control of keratinocyte differentiation and proliferation by transcription factor FOXQ1
-
批准号:10717982
-
项目类别:
-
资助金额:$51.31万
-
财政年份:2023
-
负责人:Mikhail Nikiforov
-
依托单位:
Regulation and Function of Very Long Chain Fatty Acid Biosynthesis in Multiple Myeloma
-
批准号:10560857
-
项目类别:
-
资助金额:$39.12万
-
财政年份:2022
-
负责人:Mikhail Nikiforov
-
依托单位:
Regulation and Function of Very Long Chain Fatty Acid Biosynthesis in Multiple Myeloma
-
批准号:10441549
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2022
-
负责人:Mikhail Nikiforov
-
依托单位:
Regulation and Function of Very Long Chain Fatty Acid Biosynthesis in Multiple Myeloma
-
批准号:10317554
-
项目类别:
-
资助金额:$38.43万
-
财政年份:2021
-
负责人:Mikhail Nikiforov
-
依托单位:
GMPS-GMPR axis melanoma progression and therapy
-
批准号:9920697
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2018
-
负责人:Mikhail Nikiforov
-
依托单位:
GMPS-GMPR Axis Melanoma Progression and Therapy
-
批准号:10560855
-
项目类别:
-
资助金额:$39.24万
-
财政年份:2018
-
负责人:Mikhail Nikiforov
-
依托单位:
Inhibition of MYC interactions with chromatin-remodeling factors as a novel anti-melanoma strategy
-
批准号:9808913
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2017
-
负责人:Mikhail Nikiforov
-
依托单位:
Inhibition of MYC interactions with chromatin-remodeling factors as a novel anti-melanoma strategy
-
批准号:9380591
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2017
-
负责人:Mikhail Nikiforov
-
依托单位:
KLF9-TXNRD2 axis in melanoma progression and metastasis
-
批准号:9108882
-
项目类别:
-
资助金额:$40.68万
-
财政年份:2015
-
负责人:Mikhail Nikiforov
-
依托单位:
KLF9-dependent pathways in multiple myeloma drug resistance
-
批准号:9806425
-
项目类别:
-
资助金额:$37.08万
-
财政年份:2015
-
负责人:Mikhail Nikiforov
-
依托单位:
KLF9-TXNRD2 axis in melanoma progression and metastasis
-
批准号:9291436
-
项目类别:
-
资助金额:$40.64万
-
财政年份:2015
-
负责人:Mikhail Nikiforov
-
依托单位:
Oncogene c-Myc-dependent pathways in cutaneous melanoma
-
批准号:8010153
-
项目类别:
-
资助金额:$32.06万
-
财政年份:2008
-
负责人:Mikhail Nikiforov
-
依托单位:
Oncogene c-Myc-dependent pathways in cutaneous melanoma
-
批准号:7329158
-
项目类别:
-
资助金额:$31.86万
-
财政年份:2008
-
负责人:Mikhail Nikiforov
-
依托单位:
Oncogene c-Myc-dependent pathways in cutaneous melanoma
-
批准号:7760083
-
项目类别:
-
资助金额:$32.65万
-
财政年份:2008
-
负责人:Mikhail Nikiforov
-
依托单位:
Oncogene c-Myc-dependent pathways in cutaneous melanoma
-
批准号:7623166
-
项目类别:
-
资助金额:$32.25万
-
财政年份:2008
-
负责人:Mikhail Nikiforov
-
依托单位:
Oncogene c-Myc-dependent pathways in cutaneous melanoma
-
批准号:7201972
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2006
-
负责人:Mikhail Nikiforov
-
依托单位:
Oncogene c-Myc-dependent pathways in cutaneous melanoma03
-
批准号:8894147
-
项目类别:
-
资助金额:$3.49万
-
财政年份:2006
-
负责人:Mikhail Nikiforov
-
依托单位:
Oncogene c-Myc-dependent pathways in cutaneous melanoma03
-
批准号:8974812
-
项目类别:
-
资助金额:$32.04万
-
财政年份:2006
-
负责人:Mikhail Nikiforov
-
依托单位:
Oncogene c-Myc-dependent pathways in cutaneous melanoma03
-
批准号:8238865
-
项目类别:
-
资助金额:$32.06万
-
财政年份:2006
-
负责人:Mikhail Nikiforov
-
依托单位:
海外基金